Cardiovascular Effectiveness of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Routine Care of Frail People with Type 2 Diabetes

被引：0
|
作者：
Kutz, Alexander
Gopalakrishnan, Chandrasekar
Kim, Dae H.
Patorno, Elisabetta
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-1082-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1082-P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Comparative safety and efficacy analysis of GLP-1 receptor agonists and SGLT-2 inhibitors among frail individuals with type 2 diabetes in the era of continuous population ageing
    Karakasis, Paschalis
    Patoulias, Dimitrios
    Ruza, Ieva
    Marra, Alberto Maria
    Gomez-Huelgas, Ricardo
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2025, 131 : 162 - 165
  • [32] SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease
    Sajja, Aparna P.
    Dey, Amit K.
    Guha, Avirup
    Elnabawi, Youssef
    Joshi, Aditya A.
    Kalra, Ankur
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2019, 24 (05) : 422 - 427
  • [33] Cardio-Renal Benefits of GLP-1 Receptor Agonists vs. SGLT-2 Inhibitors in Type 2 Diabetes: Are They Juxtaposed?
    Singh, Awadhesh Kumar
    Shah, Viral N.
    CLINICAL DIABETOLOGY, 2022, 11 (04): : 215 - 221
  • [34] An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
    Kilickap, Mustafa
    Kayikcioglu, Meral
    Tokgozoglu, Lale
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2021, 25 (02): : 61 - +
  • [35] Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
    Scheen, Andre J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 143 : 88 - 100
  • [36] Efficacy of GLP-1 receptor agonists and SGLT-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
    Azhie, A.
    Gupta, S.
    Misra, S.
    Chen, S.
    Meerasa, A.
    Dash, S.
    Woo, M.
    Bhat, M.
    TRANSPLANTATION, 2022, 106 (8S) : 103 - 103
  • [37] Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
    Longato, Enrico
    Di Camillo, Barbara
    Sparacino, Giovanni
    Gubian, Lorenzo
    Avogaro, Angelo
    Fadini, Gian Paolo
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)
  • [38] Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
    Lugner, Moa
    Sattar, Naveed
    Miftaraj, Mervete
    Ekelund, Jan
    Franzen, Stefan
    Svensson, Ann-Marie
    Eliasson, Bjoern
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [39] Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
    Moa Lugner
    Naveed Sattar
    Mervete Miftaraj
    Jan Ekelund
    Stefan Franzén
    Ann-Marie Svensson
    Björn Eliasson
    Cardiovascular Diabetology, 20
  • [40] The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
    Zengguang Kuang
    Ningning Hou
    Chengxia Kan
    Fang Han
    Hongyan Qiu
    Xiaodong Sun
    International Urology and Nephrology, 2023, 55 : 617 - 629
12345